Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm based in London - Enters into a Master Translational Research Services Agreement with the University of Pennsylvania. Partnership intends to advance the Chimeric Antigen Receptor T-cells developed by the company toward and through clinical trials. Outcome of agreement is the clinical proof of concept for HEMO-CAR-T, including its variations such as SAFE-HEMO-CAR-T, for the treatment of acute myeloid leukemia.
"This is the next incredibly important step on a direct path to clinical proof of concept for one of our leading product candidates. We are very pleased to be collaborating with Penn, which was the first institution to develop CAR-T technology into an approved treatment for leukemias, and which has already saved so many lives. We are confident that this collaboration will further accelerate the development of our CAR-T product candidate, which we believe will have a significant and positive impact in the treatment of acute myeloid leukemia, for which there is currently no real effective treatment," says Chief Executive Officer Vladislav Sandler.
Current stock price: 8.80 pence
Year-to-date change: down 7.4%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hemogenyx (HEMO)